The FDA's REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In 2024, several research and pharmacological ...

Air pollution exposure is associated with an increased risk of developing Parkinson disease (PD) and dyskinesia, according to study results published in JAMA Network Open.

A new study published in the Asian Journal of Psychiatry showed that people of Indian heritage require lower effective ...

People with chronic cocaine use can experience cognitive impairments and motor dysfunction that can be mitigated with antioxidant or anti-inflammatory agents; this supports the authors’ claim that ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said data from Phase 3 KINECT-3 and KINECT-4 studies showed that treatment with Ingrezza brought holistic improvements over time in patients with ...

Lyu X, Li Z, Chen S, et al. Transcranial direct current stimulation improves tardive dyskinesia in long-term hospitalized patients with chronic schizophrenia. Clin Neurophysiol. 2024;166:20-30. doi:10 ...

A 28-year-old Middle Eastern man develops severe motor disturbances, including muscle rigidity, tremors, a parkinsonian gait, and involuntary, jerky limb movements, following the administration of a 3 ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new patient- and physician-reported ...

The approval marks the first time gene therapy will be available to treat patients with aromatic I-amino acid decarboxylase ...

US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...

SAN DIEGO - Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) revealed study results indicating that nearly 60% of participants achieved remission of tardive dyskinesia after 48 weeks of ...